In July 2021, the UK Office of Life Sciences (OLS)1 published a Life Sciences Vision for the UK highlighting key areas for action. The report specifically flagged reducing morbidity and mortality from respiratory disease as one of the seven healthcare mission priorities. In addition, the report emphasised more generally the need to support underpinning infrastructure to enable better use of health data and genomic data and increasing the efficiency of clinical research delivery to improve healthcare. The importance of a flourishing respiratory disease research community in the UK has also been bought into sharp focus by the COVID-19 pandemic. The UK has achieved international acclaim for its ability to deliver definitive therapeutic trials in COVID-19 and has also made major investments into research on long COVID-19 through UKRI and NIHR which will further inform clinical practice. There remains however a key question: how well prepared is the respiratory research community to deliver on the OLS vision? Some further insights on the state of UK respiratory research can be gained from two recent consultation exercises. The first of these was designed to identify priority areas for attention and took place between 2017 and late 2019 by a group brought together under the informal auspices of the UK Respiratory Research Collaborative (UKRRC). It included two multidisciplinary open sessions held at the winter British Thoracic Society meeting and meetings with key stakeholders including major respiratory charities and a range of opinion leaders. Unfortunately, the pandemic intervened before this work was completed, but nevertheless it provided valuable stakeholder insights. A further high-level round table meeting with government convened by Asthma+Lung UK reinforced the need for a new approach. In this article, we summarise the main messages which came out of the consultations undertaken by UKRRC and Asthma+Lung UK and review the changes brought …

中文翻译：

---

英国的呼吸研究：未来 10 年的投资

2021 年 7 月，英国生命科学办公室 (OLS)1 发布了英国生命科学愿景，强调了关键的行动领域。该报告特别将降低呼吸道疾病的发病率和死亡率列为七项医疗保健任务的优先事项之一。此外，该报告更广泛地强调了支持基础设施的必要性，以更好地利用健康数据和基因组数据，并提高临床研究交付的效率以改善医疗保健。COVID-19 大流行也使英国蓬勃发展的呼吸道疾病研究社区的重要性成为人们关注的焦点。英国因其在 COVID-19 中进行确定性治疗试验的能力而获得国际赞誉，并且还通过 UKRI 和 NIHR 对长期 COVID-19 的研究进行了大量投资，这将进一步为临床实践提供信息。然而，仍然存在一个关键问题：呼吸研究界对实现 OLS 愿景的准备情况如何？从最近的两次咨询活动中可以进一步了解英国呼吸研究的状况。其中第一项旨在确定需要关注的优先领域，并在 2017 年至 2019 年底期间由一个在英国呼吸研究合作组织 (UKRRC) 非正式主持下召集的小组进行。它包括在冬季英国胸科学会会议上举行的两场多学科公开会议，以及与包括主要呼吸慈善机构和一系列意见领袖在内的主要利益相关者的会议。不幸的是，大流行病在这项工作完成之前就介入了，但它仍然为利益相关者提供了宝贵的见解。由 Asthma+Lung UK 召集的与政府的进一步高级别圆桌会议强调了对新方法的需求。在本文中，我们总结了 UKRRC 和 Asthma+Lung UK 进行的磋商所产生的主要信息，并回顾了带来的变化…… 由 Asthma+Lung UK 召集的与政府的进一步高级别圆桌会议强调了对新方法的需求。在本文中，我们总结了 UKRRC 和 Asthma+Lung UK 进行的磋商所产生的主要信息，并回顾了带来的变化…… 由 Asthma+Lung UK 召集的与政府的进一步高级别圆桌会议强调了对新方法的需求。在本文中，我们总结了 UKRRC 和 Asthma+Lung UK 进行的磋商所产生的主要信息，并回顾了带来的变化……